HIV Treatment
World AIDS Day: 18 Million Now on HIV Treatment but Many Still Lack Access
- Details
- Category: HIV Treatment
- Published on Tuesday, 29 November 2016 00:00
- Written by HIVandHepatitis.com
Thursday, December 1, is World AIDS Day, an opportunity to remember those lost to the epidemic and to focus on the continuing challenges of universal HIV prevention and treatment. According to a new report from UNAIDS, approximately 37 million people are living with HIV worldwide -- of whom more than 18 million are receiving antiretroviral therapy -- and there were about 2 million new infections in 2015.
HIV Glasgow: 4-Days-On-3-Days-Off HIV Treatment Controls Viral Load in Pilot Study
- Details
- Category: HIV Treatment
- Published on Monday, 14 November 2016 00:00
- Written by Keith Alcorn
An experimental "4 days on, 3 days off" antiretroviral regimen kept viral load fully suppressed in 96% of people for 48 weeks in a French study presented at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow) last week. The study recruited people whose viral load had been fully suppressed on standard treatment for a median of 4 years, not people who had started therapy recently.
HIV Glasgow: Darunavir/Ritonavir + Lamivudine Matches Triple-Drug HIV Therapy
- Details
- Category: Approved HIV Drugs
- Published on Monday, 07 November 2016 00:00
- Written by Keith Alcorn
Simplifying antiretroviral therapy to a 2-drug combination of lamivudine plus the protease inhibitor darunavir (Prezista) boosted by ritonavir is just as effective as a 3-drug regimen in people with suppressed viral load, Spanish investigators reported at the International Congress on Drug Therapy in HIV infection (HIV Glasgow) last month in Glasgow.
HIV Glasgow: Long-Acting HIV Fusion Inhibitor Albuvirtide Regimen Matches Standard Therapy
- Details
- Category: Experimental HIV Drugs
- Published on Monday, 07 November 2016 00:00
- Written by Keith Alcorn
A new fusion inhibitor, albuvirtide, under development in China, combined with a boosted protease inhibitor, proved just as effective as a triple regimen of lopinavir/ritonavir plus 2 NRTIs for treatment-experienced HIV patients, according to a report at the International Congress on Drug Therapy in HIV Infection last month in Glasgow.
IDWeek 2016: Tenofovir Alafenamide Works Well and Improves Kidney and Bone Markers in Older HIV Patients
- Details
- Category: Approved HIV Drugs
- Published on Sunday, 06 November 2016 00:00
- Written by Liz Highleyman
A coformulation of tenofovir alafenamide (TAF) plus emtricitabine, used with a third antiretroviral drug, maintained viral suppression as well as tenofovir disoproxil fumarate (TDF) plus emtricitabine in older individuals, and was associated with improvements in kidney function and bone density, which may be of greater concern for this group, according to a presentation last week at IDWeek 2106 in New Orleans.
Web Design and Development by